Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis

Elizabeth Harlan Michelle, Iago Pinal-Fernandez, Maria Casal-Dominguez, Jemima Albayda, Julie J. Paik, Eleni Tiniakou, Brittany Adler, Christopher A. Mecoli, Sonye K. Danoff, Lisa Christopher-Stine, Andrew L. Mammen, Thomas E. Lloyd

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Objectives: Sporadic inclusion body myositis (IBM) is the most common acquired myopathy in individuals older than 50 years. The disorder is slowly progressive, and although many therapies have been investigated, response has generally been poor. Clinical heterogeneity may influence treatment responsiveness; however, data regarding heterogeneity in IBM are limited and often conflicting. We aim to identify clinically distinct subgroups within a large IBM cohort and prognostic factors for disease progression. Methods: Clinical, histologic, radiologic, and electrophysiologic data were analyzed for all patients with IBM and other forms of myositis enrolled in a longitudinal cohort from The Johns Hopkins Myositis Center from 2003 to 2018. Patients with IBM were included if they met at least one of the following criteria: Griggs possible, European Neuromuscular Centre 2011 probable, or Lloyd-Greenberg data-derived criteria for IBM. Univariate, multivariate, and graphical analyses were used to identify prognostic factors in patients with IBM. Thus, linear and logistic regressions were used to adjust for potential confounding variables. The evolution of creatine kinase and muscle strength was studied using multilevel linear regression models. Nonmodifiable risk factors (sex, race, disease duration, and age at the onset of first symptoms) were used as adjusting covariates for the regression analyses. Results: Among the 335 patients meeting the inclusion criteria for IBM, 64% were male with an average age of disease onset of 58.7 years and delay to diagnosis of 5.2 years. Initial misdiagnosis (52%) and immunosuppressant treatment (42%) were common. Less than half (43%) of muscle biopsies demonstrated all 3 pathologic hallmarks: endomysial inflammation, mononuclear cell invasion, and rimmed vacuoles. Black patients had significantly weaker arm abductors, hip flexors, and knee flexors compared with non-Black patients. Female patients had stronger finger flexors and knee extensors compared with their male counterparts. Younger age (<50 years) at onset was not associated with increased weakness. Discussion: Our study demonstrates that female and Black patients have distinct clinical phenotypes and trajectories within the overarching IBM clinical phenotype. These subgroups may have different responses to therapies, which may influence the design of future clinical trials in IBM.

Original languageEnglish (US)
Pages (from-to)E1406-E1417
JournalNeurology
Volume100
Issue number13
DOIs
StatePublished - Mar 28 2023

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis'. Together they form a unique fingerprint.

Cite this